Previous 10 | Next 10 |
Without a doubt, 2020 has been a unique year, with many challenges for investors in both markets and personal lives. 2020 has been a very volatile year, however I managed to achieve a total return of 49.2% over the year across seven different strategies (US and Canadian), all beating ...
Gainers: Ocugen (OCGN) +114%.Big Rock Partners Acquisition (BRPA) +110%.Aurora Mobile (JG) +50%.Aqua Metals (AQMS) +45%.NantHealth (NH) +39%.Sportsman's Warehouse Holdings (SPWH) +37%.Aemetis (AMTX) +30%.Foresight Autonomous Holdings (FRSX) +29%.QuantumScape (QS) +28%.Cyclacel Pharmaceut...
Gainers: Ocugen (OCGN) +90%, NantHealth (NH) +35%, Organovo (ONVO) +25%, Genprex (GNPX) +23%, Spero Therapeutics (SPRO) +14%.Losers: Soligenix (SNGX) -54%, SOS (SOS) -39%, Venus Concept (VERO) -23%, BioCryst Pharmaceuticals...
NantHealth (NH) is up +54.1% after the company announced treatment insights on the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the clinical and cost benefits of biosimilars.The study based on data from Eviti Connect, an evidence-based treatment deci...
Gainers: Sonoma Pharmaceuticals (SNOA) +87%.aTyr Pharma (LIFE) +65%.NantHealth (NH) +63%.vTv Therapeutics (VTVT) +55%.Equus Total Return (EQS) +45%Hancock Jaffe Laboratories (HJLI) +34%.MDJM (MDJH) +25%.Foresight Autonomous (FRSX) +23%.Solid Biosciences (SLDB) +22%.22...
Gainers: Sonoma Pharmaceuticals (SNOA) +114%. NantHealth (NH) +110%. vTv Therapeutics (VTVT) +59%. aTyr Pharma (LIFE) +33%. NantKwest (NK) +22%.Losers: SELLAS Life Sciences (SLS) -33%. Immutep (IMMP) -29%. Salarius Pharmaceuticals (SLRX) -29%. Nabriva Therapeutics (NBRV) -29%. ALX O...
NantHealth’s study data shows: Adoption of trastuzumab biosimilars in treatment of HER2-positive breast cancer is significant; does not appear to have been affected by patient selection, stage of disease, or goals of care. Potentially significant clinical and ...
Study demonstrates the viability and value of RNA sequencing from formalin fixed samples in gaining a deeper understanding of patient disease biology and in delivering diagnostic, prognostic, and therapeutic value in a clinical setting RNA sequencing provides the potential to ...
NantHealth, Inc. (NH) Q3 2020 Earnings Conference Call November 5, 2020 4:30 P.M. ET Company Participants Robert Jaffe - Investor Relations Ron Louks - Chief Operating Officer Bob Petrou - Chief Financial Officer Conference Call Participants Gwen Shi - Cowen Presentation Operator Ladies and g...
NantHealth (NH): Q3 Non-GAAP EPS of -$0.07 in-line; GAAP EPS of -$0.10 in-line.Revenue of $18.8M (+1.1% Y/Y) beats by $0.64M.Press Release For further details see: NantHealth EPS in-line, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
HITRUST Certification validates NantHealth’s commitment to aligning with key regulations and protecting sensitive information NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions transforming complex data into actionable insights, today announced its E...
NantHealth , Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced the entry into a credit agreement for a new senior secured term loan in an aggregate principal amount of $22.5 million. The company...
Meridian 2023 is a look into the future of network monitoring, centered around simplification The OpenNMS Group, Inc ., a subsidiary of NantHealth, Inc. (NASDAQ: NH), today announced the release of OpenNMS Meridian 2023 . With this major release, the fully open source Meri...